Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Thibaudin

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Oncoimmunology|September 20, 2023
Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancerMarion Thibaudin, Francois Ghiringhelli
Genes and Immunity|December 8, 2023
Targeting CTLA-4: a possible solution for microsatellite-stable colorectal cancerFrançois Ghiringhelli, Marion Thibaudin
Cancers|September 19, 2020
Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of ChemotherapyJean-David Fumet, Emeric Limagne, Marion Thibaudin, et al.
STAR Protocols|November 1, 2023
Protocol for simultaneous analysis of peripheral and intratumoral lymphocyte function by flow cytometrySusy Daumoine, Léa Hampe, Emeric Limagne, et al.
Cancer Immunology, Immunotherapy : CII|March 16, 2022
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancerMarion Thibaudin, Emeric Limagne, Léa Hampe, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2020
Immunological features of coronavirus disease 2019 in patients with cancerMarion Thibaudin, Jean-David Fumet, Marjorie Bon, et al.
BMC Cancer|August 12, 2020
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatmentJean-David Fumet, Emeric Limagne, Marion Thibaudin, et al.
Journal for Immunotherapy of Cancer|June 4, 2021
Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancerQuentin Klopfenstein, Valentin Derangère, Laurent Arnould, et al.
Oncoimmunology|March 26, 2019
Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patientsEmeric Limagne, Corentin Richard, Marion Thibaudin, et al.
Oncoimmunology|March 5, 2016
Human ectonucleotidase-expressing CD25<sup>high</sup> Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functionsMarion Thibaudin, Marie Chaix, Romain Boidot, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Oncoimmunology|September 20, 2023
Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancerMarion Thibaudin, Francois Ghiringhelli
Genes and Immunity|December 8, 2023
Targeting CTLA-4: a possible solution for microsatellite-stable colorectal cancerFrançois Ghiringhelli, Marion Thibaudin
Cancers|September 19, 2020
Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of ChemotherapyJean-David Fumet, Emeric Limagne, Marion Thibaudin, et al.
STAR Protocols|November 1, 2023
Protocol for simultaneous analysis of peripheral and intratumoral lymphocyte function by flow cytometrySusy Daumoine, Léa Hampe, Emeric Limagne, et al.
Cancer Immunology, Immunotherapy : CII|March 16, 2022
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancerMarion Thibaudin, Emeric Limagne, Léa Hampe, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2020
Immunological features of coronavirus disease 2019 in patients with cancerMarion Thibaudin, Jean-David Fumet, Marjorie Bon, et al.
BMC Cancer|August 12, 2020
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatmentJean-David Fumet, Emeric Limagne, Marion Thibaudin, et al.
Journal for Immunotherapy of Cancer|June 4, 2021
Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancerQuentin Klopfenstein, Valentin Derangère, Laurent Arnould, et al.
Oncoimmunology|March 26, 2019
Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patientsEmeric Limagne, Corentin Richard, Marion Thibaudin, et al.
Oncoimmunology|March 5, 2016
Human ectonucleotidase-expressing CD25<sup>high</sup> Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functionsMarion Thibaudin, Marie Chaix, Romain Boidot, et al.
Pageof 4